C84.75 Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb

Name of the Condition

• Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb (ICD-10 Code: C84.75)

Summary

Anaplastic large cell lymphoma (ALCL), ALK-negative, is a rare type of non-Hodgkin lymphoma that originates from T-cells or null cells. It is characterized by the presence of large, abnormal lymphoid cells and typically presents as a systemic disease, though cutaneous involvement may occur. The condition is aggressive and requires prompt evaluation and management.

Causes

The exact cause of ALK-negative ALCL is not fully understood. It is believed to involve genetic mutations in lymphoid cells, which lead to uncontrolled growth and accumulation. Environmental factors or chronic antigen stimulation may contribute to its development, though specific triggers remain unclear.

Risk Factors

• Age: More common in adults, particularly those over 60.
• Immunosuppression: Conditions or treatments that weaken the immune system.
• Genetic predispositions: Family history of lymphoma or related disorders.
• Prior lymphoid disorders: History of other lymphoid malignancies may increase risk.

Symptoms

• Swollen lymph nodes or masses in affected areas.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Skin lesions, rashes, or nodules (if cutaneous involvement is present).
• Fatigue, loss of appetite, and general malaise.
• Organ-specific symptoms (e.g., pain or swelling in the inguinal region or lower limb).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and tissue biopsy. Histopathological examination of lymph node or tissue samples is essential to identify characteristic large, abnormal cells. Immunohistochemistry and molecular testing may be used to confirm ALK-negative status and rule out other lymphomas.

Treatment Options

Treatment typically includes systemic chemotherapy, often with regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Targeted therapies or immunotherapies may be considered for refractory or relapsed cases. Radiation therapy may be used for localized disease or symptom control. Treatment plans are individualized based on disease stage and patient factors.

Prognosis and Follow-Up

Prognosis varies depending on disease stage, response to treatment, and patient health. ALK-negative ALCL is generally more aggressive than ALK-positive subtypes. Regular follow-up with imaging and clinical assessments is necessary to monitor for recurrence or progression. Long-term surveillance is recommended due to the risk of relapse.

Complications

• Disease progression or recurrence.
• Treatment-related side effects (e.g., infection, organ toxicity).
• Secondary malignancies from chemotherapy or radiation.
• Lymphedema or functional impairment in the affected limb.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known immunosuppressive exposures when possible.
• Seek prompt medical evaluation for persistent lymph node swelling or systemic symptoms.
• Follow recommended cancer screening guidelines based on individual risk factors.

When to Seek Professional Help

• Unexplained, persistent swelling in the inguinal region or lower limb.
• Systemic symptoms like fever, night sweats, or unexplained weight loss.
• New or changing skin lesions, especially with lymphoma history.
• Signs of infection or severe treatment side effects during therapy.

Tips for Medical Coders

Document the specific site (inguinal region and lower limb) clearly in the medical record to support code assignment. Ensure biopsy results and clinical findings confirm ALK-negative status. Code C84.75 is specific to lymph nodes in this region; verify no other site codes apply. Include details on disease extent (e.g., localized vs. systemic) for accurate coding and reporting.